MXCT MAXCYTE, INC.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1287098 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.1%
TTM net income YoY38.7%
TTM EPS YoY39.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin81.0%
Operating margin-98.0%
Net margin-81.4%
FCF margin-62.4%
EBITDA margin-86.5%
Returns
ROE-16.9%
ROA-14.1%
ROIC (approx.)-17.5%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio7.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $33.03M | $38.63M |
| Cost of revenue | $6.22M | $7.10M |
| Gross profit | $26.80M | $31.53M |
| R&D expense | $20.82M | $22.23M |
| SG&A expense | $28.12M | $29.69M |
| Operating income | -$51.90M | -$51.20M |
| Pretax income | -$44.63M | -$41.05M |
| Net income | -$44.63M | -$41.05M |
| EBITDA | -$47.56M | -$46.88M |
| EPS (basic) | -0.42 | -0.39 |
| EPS (diluted) | -0.42 | -0.39 |
| Weighted avg. shares (diluted) | 106.43M | 104.85M |
| Balance sheet | ||
| Cash & equivalents | $20.07M | $27.88M |
| Short-term investments | $82.98M | $126.60M |
| Receivables | $3.50M | $4.68M |
| Inventory | $7.55M | $8.91M |
| Current assets | $118.37M | $171.68M |
| PP&E, net | $17.53M | $19.71M |
| Intangibles | $650,000 | — |
| Total assets | $202.51M | $239.47M |
| Current liabilities | $14.27M | $15.78M |
| Total liabilities | $31.02M | $33.22M |
| Shareholders' equity | $171.49M | $206.25M |
| Shares outstanding | 106.79M | 105.71M |
| Cash flow statement | ||
| Operating cash flow | -$34.41M | -$27.61M |
| Capital expenditure | $1.77M | $1.65M |
| Free cash flow | -$36.18M | -$29.26M |
| Investing cash flow | $25.93M | $6.93M |
| Financing cash flow | $656,000 | $2.06M |
| Depreciation & amortization | $4.34M | $4.32M |
| Stock-based compensation | $9.21M | $13.08M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.